Pathological aging is alleviated by neutralization of the autophagy-repressive tissue hormone DBI/ACBP.

Léa Montégut, Flavia Lambertucci, Lucas Moledo-Nodar, Isabelle Martins, Alejandro Lucia, Clea Barcena, Guido Kroemer

Team "Metabolism, Cancer & Immunity", Centre de Recherche des Cordeliers, Equipe Labellisée par la Ligue Contre le Cancer, Université Paris Cité, Sorbonne Université, Inserm U1138, Institut Universitaire de France, Paris, France.Team "Metabolism, Cancer & Immunity", Centre de Recherche des Cordeliers, Equipe Labellisée par la Ligue Contre le Cancer, Université Paris Cité, Sorbonne Université, Inserm U1138, Institut Universitaire de France, Paris, France. · pubmed

Paper

Abstract

DBI/ACBP (diazepam binding inhibitor, acyl CoA-binding protein) is a macroautophagy/autophagy-inhibitory tissue hormone produced by multiple cell types. The plasma levels of DBI/ACBP rise with age and disease. In centenarians living in nursing homes, DBI/ACBP concentrations are approximately threefold higher than in younger adults (30-48 years old), but these levels increase further in centenarians hospitalized due to disease exacerbation. Elevated DBI/ACBP correlates with unfavorable clinical parameters, including high Charlson Comorbidity Index, elevated neutrophil:lymphocyte ratio, and decreased renal function. In mouse models, neutralization of DBI/ACBP using monoclonal antibodies ameliorates several aging-related pathologies. In

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

Neutralization of the autophagy-repressive hormone DBI/ACBP alleviates aging-related pathologies in mouse models. The paper addresses a potential root cause of aging by exploring the role of DBI/ACBP in autophagy regulation and its implications for age-related diseases, making it relevant to longevity research.

Author of this paper? Send a correction.